JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 47 citations in OpenAlex.

1. LC-QQQ serum metabolomics reveals disease-specific metabolic signatures and diagnostic metabolite panels distinguishing polycythaemia vera from secondary polycythaemia.Metabolomics : Official journal of the Metabolomic Society · 2026
   Article
2. Advancements and Future Directions in Polycythemia Vera Research: A Bibliometric Analysis.Cureus · 2024
   Review
3. JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2014
   Article
4. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway.Journal of cellular and molecular medicine · 2012
   Article
5. Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.Medical oncology (Northwood, London, England) · 2011
   Article
6. Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera.Molecular medicine (Cambridge, Mass.) · 2011
   Article
7. The history of myeloproliferative disorders: before and after Dameshek.Leukemia · 2008
   Review
8. Congenital and acquired polycythemias.Deutsches Arzteblatt international · 2008
   Article
9. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.Leukemia · 2008
   Review
10. Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.Experimental hematology · 2007
    Article

Corrections and comments

• Comment on
  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.2007

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as